Literature DB >> 8782146

Non-Hodgkin's lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate.

A R Usman1, M B Yunus.   

Abstract

We describe 2 patients who developed non-Hodgkin's lymphoma during treatment with low dose methotrexate (MTX) for rheumatoid arthritis (RA). A review of the literature identified 16 more cases published in English. Among these 18 patients, the mean RA duration was 16 yrs and lymphoma developed after a mean of 2.8 yrs of treatment with MTX. The mean total dose of MTX was 1224 mg. Although 3 patients had spontaneous regression of lymphoma, 5 of the 18 patients died. It is not known whether there is cause-effect relationship between MTX and lymphoma among patients with RA. Special awareness of this possible complication of MTX is important.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8782146

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  9 in total

1.  Anaplastic large cell lymphoma in a patient with rheumatoid arthritis taking low dose methotrexate.

Authors:  Seong-Kyu Kim; In Soon Kim; Jae-Bum Jun
Journal:  Rheumatol Int       Date:  2005-09-27       Impact factor: 2.631

Review 2.  Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Jill Koshiol; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

3.  Survival patterns in patients with Hodgkin's lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease.

Authors:  Ola Landgren; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

Review 4.  Autoimmunity and lymphomagenesis.

Authors:  Lynn R Goldin; Ola Landgren
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

Review 5.  Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives?

Authors:  Alexandros Drosos
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

6.  Anaplastic large cell lymphoma in a patient with rheumatoid arthritis.

Authors:  Cemal Bes; Z Senem Bes; Seref Vardı; Mehmet Soy
Journal:  Rheumatol Int       Date:  2009-10-23       Impact factor: 2.631

Review 7.  Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/ Waldenström's macroglobulinemia.

Authors:  Sigurdur Y Kristinsson; Jill Koshiol; Lynn R Goldin; Magnus Björkholm; Ingemar Turesson; Gloria Gridley; Mary L McMaster; Ola Landgren
Journal:  Clin Lymphoma Myeloma       Date:  2009-03

8.  Methotrexate at middle and high accumulative doses might be associated with lower risk of new-onset cancers in patients with rheumatoid arthritis: a nationwide population-based cohort study.

Authors:  Wuu-Tsun Perng; Yao-Min Hung; Renin Chang; Cheng-Li Lin; Jeng-Yuan Chiou; Huang-Hsi Chen; Chia-Hung Kao; James Cheng-Chung Wei
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-29       Impact factor: 5.346

9.  Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report.

Authors:  Takeshi Kuroda; Hiroe Sato; Takeshi Nakatsue; Yoko Wada; Shuichi Murakami; Masaaki Nakano; Ichiei Narita
Journal:  BMC Res Notes       Date:  2014-04-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.